A5021016682- COVID-19 Clinical Research Studies
- Liver Disease Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Lung Cancer Treatments and Mutations
- HIV Research and Treatment
- Diagnosis and treatment of tuberculosis
- Infectious Diseases and Tuberculosis
- HIV/AIDS Research and Interventions
- Coronary Interventions and Diagnostics
- Cancer Genomics and Diagnostics
- Hepatitis C virus research
- Tuberculosis Research and Epidemiology
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 and healthcare impacts
- Cardiac Imaging and Diagnostics
- Pneumonia and Respiratory Infections
- Streptococcal Infections and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Antibiotic Use and Resistance
- Hepatitis B Virus Studies
- Pharmaceutical Economics and Policy
- Healthcare cost, quality, practices
- Cervical Cancer and HPV Research
- Cardiac and Coronary Surgery Techniques
- Autoimmune and Inflammatory Disorders Research
Center for Global Health
2024
VIR Biotechnology (United States)
2022-2023
Roche (United States)
2018-2022
La Roche College
2022
Roche (Switzerland)
2019-2020
Materials Systems (United States)
2020
Istanbul University
1993-2015
Abbott (United States)
2014
Abbott Vascular (United States)
2014
University of Washington
2009-2012
Sotrovimab, a recombinant human monoclonal antibody (mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had US Food and Drug Administration Emergency Use Authorization for the treatment of high-risk outpatients with mild-to-moderate disease 2019 (COVID-19) from 26 May 2021 to 5 April 2022. Real-world clinical effectiveness sotrovimab in reducing risk 30-day all-cause hospitalization and/or mortality was evaluated period when prevalence circulating SARS-CoV-2 variants...
ABSTRACT Background Sotrovimab, a recombinant human monoclonal antibody (mAb) against SARS-CoV-2 had US FDA Emergency Use Authorization (EUA) for the treatment of high-risk outpatients with mild- to-moderate COVID-19 from May 26, 2021 to April 5, 2022. The study objective was evaluate real-world effectiveness sotrovimab in reducing risk 30-day all-cause hospitalization and/or mortality during time period when prevalence circulating variants changing between Delta and Omicron sub-lineages US....
Abstract Background The real-world clinical effectiveness of sotrovimab in preventing coronavirus disease 2019 (COVID-19)–related hospitalization or mortality among high-risk patients diagnosed with COVID-19, particularly after the emergence Omicron variant, needs further research. Method Using data from US Department Veterans Affairs (VA) health care system, we adopted a target trial emulation design our study. aged ≥18 years, COVID-19 between December 1, 2021, and April 4, 2022, were...
Advances in personalized medicine are supported by companion diagnostic molecular tests. Testing accuracy is critical for selecting patients optimal therapy and reducing treatment-related toxicity. We assessed the clinical economic impact of inaccurate test results between laboratory developed tests (LDTs) a US Food Drug Administration (FDA)-approved detection epidermal growth factor receptor (EGFR) mutations. Using hypothetical cohort newly diagnosed metastatic non-small cell lung cancer...
Coronavirus disease 2019 (COVID-19) has imposed a considerable burden on the United States (US) health system, with particular concern over healthcare capacity constraints. We modeled impact of public and private sector contributions to developing diagnostic testing treatments COVID-19-related resource use. estimated that led at least 30% reductions in utilization. Private expanded further mortality (- 44%), intensive care unit (ICU) non-ICU hospital beds - 28%, respectively), ventilator use...
This retrospective observational study evaluated outpatient treatment patterns among patients with molecular-based viral diagnostic testing for suspected upper respiratory tract infections in the United States. Patients a test were identified from 1 August 2016 to July 2019 large national reference laboratory database linked IQVIA's prescription and medical claims databases. Antibiotic influenza antiviral reported up 7 days post-test result. Predictors of antibiotic utilization assessed...
In the United States, approximately 12 million individuals seek medical care for pharyngitis each year, accounting about 2% of ambulatory visits. Although gold standard diagnosing group A streptococcus (GAS) is culture, it time intensive. Rapid antigen detection tests (RADT) with or without culture confirmation are commonly used instead. RADT provide results quickly, they generally have lower test sensitivity. Recently, point-of-care nucleic acid amplification (POC NAAT) emerged. This study...
ABSTRACT Background Data on effectiveness of sotrovimab preventing COVID-19-related hospitalization or mortality, particularly after the emergence Omicron variant, are limited. Method Determine real-world clinical for prevention 30-day COVID-19 related mortality using a retrospective cohort within U.S. Department Veterans Affairs (VA) healthcare system. aged ≥18 years, diagnosed with between December 1, 2021, and April 4, 2022, were included. Sotrovimab recipients (n=2,816) exactly matched...
Aims: Endobronchial involvement may occur in patients with sarcoidosis. Although the prevalence of bronchial abnormalities is high, there are no firm data establishing clinical features and prognosis sarcoidosis these patients. The aim our study was to define characteristics endobronchial Methods: Clinical laboratory findings 44 46 without seen at institution, were evaluated retrospectively. fulfilled clinical, radiologic or both supported by histopathologic evidence noncaseating granulomas....
Within the European Union, Greece has highest incidence of lung cancer among people under 45 years age. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are indicated for treatment patients with EGFR mutation-positive metastatic non-small cell (mNSCLC). Tumor tissue biopsy is standard method mutation detection but invasive, resource-intensive, and risks complications. The objective this analysis was to estimate financial impact on Greek National Health System adopting...
Small bowel perforation is a rare complication of miliary tuberculosis. We report the case 21-year old patient who developed small 70 days after initiation adequate tuberculosis treatment. also present review literature.
Objectives Pakistan has a hepatitis C virus (HCV) infection prevalence of 6%–9% and aims to achieve World Health Organisation (WHO) targets for elimination HCV by the year 2030. We aim evaluate potential cost-effectiveness reference laboratory-based (centralised laboratory testing; CEN) confirmatory testing approach versus molecular near-patient point-of-care (POC) screen general population in Pakistan. Study design used decision tree-analytic model from governmental (formal healthcare...